2021
DOI: 10.1055/s-0041-1736682
|View full text |Cite
|
Sign up to set email alerts
|

Orbital Metastasis as Initial Clinical Presentation in a Patient of Hepatocellular Carcinoma – A Rare Case with Review of Literature

Abstract: Orbital metastasis, as the initial clinical presentation in hepatocellular carcinoma (HCC), is a rare manifestation. A 66-year-old male patient presented with a history of protrusion of the eyeballs, double vision, and swelling over the left side of the head for 8 months. Magnetic resonance imaging of the brain with orbit revealed a heterogeneous lesion in the left frontal lobe causing its destruction with intraorbital and intracranial extension. Triphasic contrast-enhanced computed tomography was suggestive o… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(3 citation statements)
references
References 27 publications
(27 reference statements)
0
3
0
Order By: Relevance
“…Dataon the optimal treatment of HCC with orbital metastasis are lacking, and therapeutic options are limited. To the best of our knowledge, only 5 patients among the 45 reported patients with advanced HCC and orbital metastasis underwent standard systemic therapy [ 4 , 12 , 13 , 33 , 34 ]. Among them, 1 patient received atezolizumab plus bevacizumab (survival of only 6 months) [ 13 ], whereas 4 received sorafenib (survival not reported).…”
Section: Discussionmentioning
confidence: 99%
See 2 more Smart Citations
“…Dataon the optimal treatment of HCC with orbital metastasis are lacking, and therapeutic options are limited. To the best of our knowledge, only 5 patients among the 45 reported patients with advanced HCC and orbital metastasis underwent standard systemic therapy [ 4 , 12 , 13 , 33 , 34 ]. Among them, 1 patient received atezolizumab plus bevacizumab (survival of only 6 months) [ 13 ], whereas 4 received sorafenib (survival not reported).…”
Section: Discussionmentioning
confidence: 99%
“…In real-world clinical practice, the affordability of both immunotherapies and targeted therapies remains challenging. Orbital RT can be performed to reduce tumor size and alleviate symptoms [12,13,[29][30][31] in cases in which surgery is contraindicated. Surgical debulking is effective in reducing tumor mass-related symptoms [20,21,29,32]; however, it could result in serious complications, including permanent visual deficits.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation